Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 17/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PKLR | P30613 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4340714 | 0.95 | BDKRB1 (0.39) | BDKRB1 | |
| SCHEMBL4338579 | 0.94 | BDKRB1 (0.38) | BDKRB1 | |
| SCHEMBL4340761 | 0.92 | BDKRB1 (0.42) | BDKRB1 | |
| SCHEMBL4338235 | 0.91 | BDKRB1 (0.38) | BDKRB1HTR6 | |
| SCHEMBL4338434 | 0.91 | BDKRB1 (0.38) | BDKRB1HTR6 | |
| SCHEMBL4331413 | 0.90 | BDKRB1 (0.38) | BDKRB1HTR6 | |
| SCHEMBL4342342 | 0.89 | BDKRB1 (0.37) | BDKRB1PKMPKLR | |
| SCHEMBL4337996 | 0.89 | BDKRB1 (0.34) | BDKRB1 | |
| SCHEMBL4339971 | 0.89 | BDKRB1 (0.42) | BDKRB1 | |
| SCHEMBL4342312 | 0.89 | BDKRB1 (0.36) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612060-B2 | Triazoles and methods of use | AMGEN INC. (US) | 2009-11-03 | — | — | US | claimed |
| EP-1817306-A1 | TRIAZOLES AND THEIR USE AS BRADYKININ B1 RECEPTOR ANTAGONISTS | Amgen, Inc (US) | 2007-08-15 | — | — | EP | claimed |
| US-20060100213-A1 | Triazoles and methods of use | AMGEN INC. (US) | 2006-05-11 | — | — | US | claimed |
| WO-2006044355-A1 | TRIAZOLES AND THEIR USE AS BRADYKININ B1 RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2006-04-27 | — | — | WO | claimed |
| US-7612060-B2 | Triazoles and methods of use | AMGEN INC. (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1817306-A1 | TRIAZOLES AND THEIR USE AS BRADYKININ B1 RECEPTOR ANTAGONISTS | Amgen, Inc (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20060100213-A1 | Triazoles and methods of use | AMGEN INC. (US) | 2006-05-11 | — | — | US | disclosed |
| WO-2006044355-A1 | TRIAZOLES AND THEIR USE AS BRADYKININ B1 RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100213-A1 | Triazoles and methods of use | CYP3A5, CYP3A43, CYP2E1 | BDKRB1 138/4885PKM 828/4885PKLR 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.